905729-22-8

Upstream product

• 251924-61-5 1-[1-(4-fluorobenzyl)-1H-pyrrol-2-yl]ethanone 
• 553-90-2 Dimethyl oxalate 
• 1072-83-9 2-Acetylpyrrole 
• 1192-62-7 1-(2-furyl)-1-ethanone 

Downstream Products

• 500366-18-7 4-[1-(4-Fluorobenzyl)-1H-pyrrole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one 

Relevant academic research and scientific papers

From ligand to complexes: Inhibition of human immunodeficiency virus type 1 integrase by β-diketo acid metal complexes

β-Diketo acid-containing compounds are a promising class of human immunodeficiency virus type 1 (HIV-1) integrase (IN) inhibitors. Starting from the hypothesis that these inhibitors are able to coordinate ions in solution before interacting on the active site, a series of potentiometric measurements have been performed to understand the coordination ability of the diketo acid pharmacophore toward the biologically relevant Mg2+. Moreover, by using β-diketo acid/ester as model ligands with a set of divalent metal ions (Mg, Mn, Ni, Co, Cu, and Zn), we obtained a series of complexes and tested them for anti-HIV-1 IN activity. Results demonstrate that the diketo acid functionality chelates divalent metal ions in solution, and complexes with metals in different stoichiometric ratios are isolated. We postulate that the diketo acids act as complexes in their active form. In particular, they predominantly form species such as Mg2L2+ and Mg 2L2 (derived from diketo acids, H2L), and MgL+ and MgL2 (derived from diketo esters, HL) at physiological pH. Furthermore, the synthesized mono- and dimetallic complexes inhibited IN at a high nanomolar to low micromolar range, with metal dependency in the phenyl diketo acid series. Retrospective analysis suggests that the electronic properties of the aromatic framework influence the metal-chelating ability of the diketo acid system. Therefore, the difference in activities is related to the complexes they preferentially form in solution, and these findings are important for the design of a new generation of IN inhibitors.

ANTIVIRAL AGENT

The present invention provides an integrase inhibitor. The inventors have have found the following compound of formula (I) possessing an integrase inhibitory activity. (wherein, R C and R D taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH ; R A is a group shown by (wherein, C ring is N-containing aromatic heterocycle) or the like)